Sandra Misale
Sandra Misale
Assistant Professor of Oncology, Johns Hopkins University School of Medicine
Zweryfikowany adres z mskcc.org
Cytowane przez
Cytowane przez
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
S Misale, R Yaeger, S Hobor, E Scala, M Janakiraman, D Liska, E Valtorta, ...
Nature 486 (7404), 532-536, 2012
Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution
S Misale, F Di Nicolantonio, A Sartore-Bianchi, S Siena, A Bardelli
Cancer discovery 4 (11), 1269-1280, 2014
Stromal microenvironment shapes the intratumoral architecture of pancreatic cancer
M Ligorio, S Sil, J Malagon-Lopez, LT Nieman, S Misale, M Di Pilato, ...
Cell 178 (1), 160-175. e27, 2019
EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer
V Amodio, R Yaeger, P Arcella, C Cancelliere, S Lamba, A Lorenzato, ...
Cancer discovery 10 (8), 1129-1139, 2020
Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer
M Russo, S Misale, G Wei, G Siravegna, G Crisafulli, L Lazzari, G Corti, ...
Cancer discovery 6 (1), 36-44, 2016
Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer
S Misale, S Arena, S Lamba, G Siravegna, A Lallo, S Hobor, M Russo, ...
Science translational medicine 6 (224), 224ra26-224ra26, 2014
Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer
S Arena, B Bellosillo, G Siravegna, A Martínez, I Canadas, L Lazzari, ...
Clinical cancer research 21 (9), 2157-2166, 2015
KRAS gene amplification in colorectal cancer and impact on response to EGFR‐targeted therapy
E Valtorta, S Misale, A Sartore‐Bianchi, ID Nagtegaal, F Paraf, ...
International journal of cancer 133 (5), 1259-1265, 2013
KRAS G12C NSCLC models are sensitive to direct targeting of KRAS in combination with PI3K inhibition
S Misale, JP Fatherree, E Cortez, C Li, S Bilton, D Timonina, DT Myers, ...
Clinical Cancer Research 25 (2), 796-807, 2019
HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers
BT Li, F Michelini, S Misale, E Cocco, L Baldino, Y Cai, S Shifman, HY Tu, ...
Cancer discovery 10 (5), 674-687, 2020
Resistance to TRK inhibition mediated by convergent MAPK pathway activation
E Cocco, AM Schram, A Kulick, S Misale, HH Won, R Yaeger, P Razavi, ...
Nature medicine 25 (9), 1422-1427, 2019
Targeting the CBM complex causes Treg cells to prime tumours for immune checkpoint therapy
M Di Pilato, EY Kim, BL Cadilha, JN Prüßmann, MN Nasrallah, ...
Nature 570 (7759), 112-116, 2019
Sensitivity to entrectinib associated with a novel LMNA-NTRK1 gene fusion in metastatic colorectal cancer
A Sartore-Bianchi, E Ardini, R Bosotti, A Amatu, E Valtorta, A Somaschini, ...
Journal of the National Cancer Institute 108 (1), djv306, 2016
Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants
MH Hofmann, D Gerlach, S Misale, M Petronczki, N Kraut
Cancer Discovery 12 (4), 924-937, 2022
Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers
S Misale, I Bozic, J Tong, A Peraza-Penton, A Lallo, F Baldi, KH Lin, ...
Nature communications 6 (1), 8305, 2015
TGFα and amphiregulin paracrine network promotes resistance to EGFR blockade in colorectal cancer cells
S Hobor, BO Van Emburgh, E Crowley, S Misale, F Di Nicolantonio, ...
Clinical Cancer Research 20 (24), 6429-6438, 2014
MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations
S Arena, G Siravegna, B Mussolin, JD Kearns, BB Wolf, S Misale, ...
Science translational medicine 8 (324), 324ra14-324ra14, 2016
Anatomic position determines oncogenic specificity in melanoma
JM Weiss, MV Hunter, NM Cruz, A Baggiolini, M Tagore, Y Ma, S Misale, ...
Nature 604 (7905), 354-361, 2022
STAT3 can serve as a hit in the process of malignant transformation of primary cells
M Demaria, S Misale, C Giorgi, V Miano, A Camporeale, J Campisi, ...
Cell Death & Differentiation 19 (8), 1390-1397, 2012
TRK xDFG mutations trigger a sensitivity switch from type I to II kinase inhibitors
E Cocco, JE Lee, S Kannan, AM Schram, HH Won, S Shifman, A Kulick, ...
Cancer discovery 11 (1), 126-141, 2021
Nie można teraz wykonać tej operacji. Spróbuj ponownie później.
Prace 1–20